Regulatory Updates

Novartis remibrutinib wins Phase 3 in chronic spontaneous urticaria

chronic spontaneous urticaria · 8 min

EMA backs datopotamab deruxtecan for advanced lung cancer

EMA · lung cancer · 10 min

FDA approves Vyloy for HER2-negative gastric and GEJ cancer

FDA · HER2-negative gastric cancer · 5 min

AbbVie closes $8.7B Cerevel deal as neuroscience pipeline expands

U.S. Federal Trade Commission · immunology · 5 min

Lenacapavir posts 100% HIV prevention in PURPOSE 1

FDA · HIV · 8 min

J&J reports positive Phase 3 Tremfya data in ulcerative colitis

CHMP · ulcerative colitis · 7 min

FDA approves Dupixent for COPD with eosinophilic phenotype

FDA · chronic obstructive pulmonary disease · 6 min

GSK Blenrep wins FDA approval in relapsed multiple myeloma

FDA · blood cancer · 6 min

Moderna's mRNA-1083 Phase 3 shows stronger flu and COVID immune responses

FDA · COVID-19 · 7 min

FDA Approves Vertex’s First-in-Class Non-Opioid Pain Drug Journavx

FDA · moderate-to-severe acute pain · 8 min

FDA approves Keytruda for adjuvant NSCLC treatment, expanding Merck’s lung cancer label

FDA · lung cancer · 6 min

Novo Nordisk CagriSema Phase 3 Results: Obesity Catalyst Update

EMA · obesity · 7 min